User:Mr. Ibrahem/Gemtuzumab ozogamicin

Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is a medication used to treat acute myeloid leukemia. Specifically it is used for CD33 positive disease. It is used together with daunorubicin and cytarabine. It is given by gradual injection into a vein.

Common side effects include infection and bleeding. Other side effects may include liver problems, QT prolongation, infertility, and tumor lysis syndrome. Use in pregnancy may harm the baby. It is a monoclonal antibiotic attached to a cytotoxin. The monoclonal antibody attaches to CD33 and the cytotoxin is calicheamicin.

Gemtuzumab ozogamicin was approved for medical use in the United States in 2017 and Europe in 2018. In the United Kingdom it costs the NHS about £6,300 per 5 mg vial as of 2021.